The global rheumatoid arthritis drugs market was valued at $57,929 million in 2019, and is projected to reach $62,935 million by 2027, registering a CAGR of 2.8% from 2020 to 2027. Alarming rise in ...

Final results from the RA-BEYOND study show that patients with rheumatoid arthritis can often maintain disease control after tapering baricitinib from 4 mg to 2 mg.

Despite writing on the autoimmune disease, even this doctor struggled to get a quick diagnosis. Eight years on, she now lives ...

Treatment with glucagon-like peptide-1 receptor agonists (GLP-1RAs) may reduce the risk of dementia or cognitive impairment.

Long-term treatment with mepolizumab, an interleukin-5 inhibitor, demonstrates a favorable safety profile and sustained corticosteroid-sparing benefits among patients with eosinophilic granulomatosis ...

Tirzepatide is approved for 3 indications in the US: type 2 diabetes, chronic weight management, and obstructive sleep apnea.